Herrick, Ariane L;
Assassi, Shervin;
Denton, Christopher P;
(2022)
Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need.
Nature Reviews Rheumatology
, 18
pp. 276-285.
10.1038/s41584-022-00765-9.
Preview |
Text
Herrick_Assassi_Denton_accepted for UCL upload March 2022.pdf - Accepted Version Download (629kB) | Preview |
Abstract
Diffuse cutaneous systemic sclerosis (dcSSc) is associated with high mortality resulting from early internal-organ involvement. Clinicians therefore tend to focus on early diagnosis and treatment of potentially life-threatening cardiorespiratory and renal disease. However, the rapidly progressive painful, itchy skin tightening that characterizes dcSSc is the symptom that has the greatest effect on patients' quality of life, and there is currently no effective disease-modifying treatment for it. Considerable advances have been made in predicting the extent and rate of skin-disease progression (which vary between patients), including the development of techniques such as molecular analysis of skin biopsy samples. Risk stratification for progressive skin disease is especially relevant now that haematopoietic stem-cell transplantation is a treatment option, because stratification will inform the balance of risk versus benefit for each patient. Measurement of skin disease is a major challenge. Results from clinical trials have highlighted limitations of the modified Rodnan skin score (the current gold standard). Alternative patient-reported and other potential outcome measures have been and are being developed. Patients with early dcSSc should be referred to specialist centres to ensure best-practice management, including the management of their skin disease, and to maximize opportunities for inclusion in clinical trials.
Archive Staff Only
 |
View Item |
